Background
Physiological function of EZH2 in lymphogenesis
EZH2 in T cells
T cell subtypes | Findings | Authors |
---|---|---|
T follicular helper cell | Ezh2 deploys H3K27 tri-methylation to repress CDKN2A expression in Tfh cells, maintaining its differentiation and activation. | Li F., et al. [4] |
T helper cell | EZH2 methylates H3K27 at the IL4-IL13 locus and represses IL4-IL13 expression in Th1 but not Th2 cells. | Koyanagi M., et al. [10] |
T helper cell | SMAD2 and SMAD4 regulate TGF-β-mediated IL9 production via EZH2 displacement in Th9 cells. | Wang A., et al. [11] |
T follicular regulatory cell | Ezh2 is required for Tfr suppressive function and transcriptional program. | Hou S., et al. [18] |
Regulatory T cell | Treg cells from EZH2 −/− FOXP3+ mice display enhanced expression of target genes shared by EZH2 and FOXP3. | Sarmento OF., et al. [17] |
Cytotoxic T cell and memory T cell | Terminal cytotoxic T cells display higher-level H3K27 tri-methylation than memory T cells and repression of memory T-specific genes. | Gray SM., et al. [5] |
T helper cell | EZH2 keeps the correct expression of transcription factor TBX21 and GATA3 as well as cytokines like IFN-γ in Th1 and Th2 cells. | Tumes DJ., et al. [7] |
Memory T cell | AKT-mediated EZH2 S21 phosphorylation attenuates EZH2 activity and enhances memory T cells to develop into T effector cells. | He S., et al. [6] |
T helper cell, regulatory T cell | EZH2 epigenetically silence IFN-γ in Th2 and Treg, and IL10 in Th2. EZH2 deficiency accelerates Th cell death via apoptosis. | Zhang Y., et al. [12] |
T helper cell, regulatory T cell | EZH2-deficient Th and Treg cells neither constrain T. gondii infection nor prevent autoimmune colitis. | Yang XP., et al. [15] |
Regulatory T cell | Polycomb epigenetically silences FOXP3 in a KLF-dependent manner. | Xiong Y., et al. [8] |
Regulatory T cell | EZH2 safeguards Treg identity by maintaining its transcriptome and thus prevents spontaneous autoimmunity. | DuPage M., et al. [16] |
Regulatory T cell | FOXP3 poises its targets for repression by recruiting EZH2 upon Treg cells activation. | Arvey A., et al. [9] |
NK T cell | EZH2 depletion disrupts the bivalent state at PRZF promoter and leads to the expression of non-NKT specific TCR. | Dobenecker MW., et al. [14] |
Naïve CD8+ T cell | EZH2 promotes naïve CD8+ T cell proliferation by epigenetically repressing the expression of CDKN1C and CDKN2A. | Chen G., et al. [13] |
EZH2 in B cells
EZH2 deregulation
Genetic and epigenetic abnormalities of EZH2
Non-genetic causes of abnormal EZH2 expression
EZH2 mediates lymphoid oncogenesis
As epigenetic modifier
Associating with long non-coding RNAs
Regulated by phosphorylation
Modulating tumor microenvironment
Connected with EBV infections
Therapeutic interventions to EZH2 signaling
EZH2 inhibitors
Inhibitor(s) | Malignancies | Authors |
---|---|---|
GSK126 | EZH2-mutant and wild-type GC-DLBCL, FL, ABC-DLBCL, T-ALL, MCL, ATLL, CTCL, MM | |
GSK343 | MM | Ezponda T., et al. [127] |
EI1 | EZH2-mutant GC-DLBCL | Qi W., et al. [128] |
EPZ-6438 | EZH2-mutant and wild-type GC-DLBCL, MM | |
EPZ005687 | EZH2-mutant and wild-type GC-DLBCL | Knutson SK., et al. [133] |
EPZ011989 | EZH2-mutant GC-DLBCL | Campbell JE., et al. [134] |
EBI-2511 | EZH2-mutant GC-DLBCL | Lu B., et al. [135] |
ZLD10A | EZH2-mutant GC-DLBCL | Song X., et al. [136] |
DCE_42/254 | EZH2-mutant and wild-type GC-DLBCL | Wu Y., et al. [137] |
CPI-1205 | EZH2-mutant GC-DLBCL | Vaswani RG., et al. [138] |
Tetramethyl-piperidinyl Benzamides | EZH2-mutant GC-DLBCL | Nasveschuk CG., et al. [139] |
Inhibiting EED
Inhibiting EZH2 upstream signaling
Combinatorial targeting with other chemotherapeutic agents
Treatment regimen(s) | Malignancies | Authors |
---|---|---|
GSK126 and Etoposide | GC-DLBCL, BL | Smonskey M., et al. [155] |
GSK126 and Pentoxifylline | MM, T-ALL | Neo WH., et al. [56] |
GSK126/EPZ-6438/DZnep and Panobinostat | MM, MCL | |
DZnep and JQ1 | BL, MCL, GC-DLBCL | Zhao X., et al. [51] |
DZnep and Daunoblastine | T-ALL | D’Angelo V., et al. [156] |
UNC1999 and Bortezomib/Carfilzomib | MM | Rizq O., et al. [154] |
DZnep and Vorinostat | MCL, BL | Zhang X., et al. [54] |
GSK126/Dznep and ACY-957/1044 | EZH2-mutant GC-DLBCL | Johnson DP., et al. [160] |